Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China

This is a Phase 3, modified double-blind, randomized, parallel-group, active-controlled, multicenter study with 2 arms and 4 groups to evaluate the immunogenicity and safety of MenACYW conjugate vaccine in children and adolescents versus control meningococcal vaccines licensed in China. Study details include: * The study duration will be approximately 180 days. * The vaccination visit will be Visit 1. * The visit frequency will be 2 on-site visits with a 30-day interval. A safety visit/telephone call is planned on the ninth day after the vaccination for all groups; a safety follow-up telephone call is planned for all groups 180 days post the last vaccination.

NCT Number	NCT07135986
Lead Sponsor	Sanofi
Conditions	Meningococcal Infection, Healthy Volunteers
Enrollment	1,602 participants
Start Date	2025-09-26
Primary Completion	2026-05-01 (estimated)
Study Completion	2026-09-23 (estimated)
Updated on ClinicalTrials.gov	2026-05-12